ArticleNeuroradiology2025
Enterprise 2 stent outcomes in hyperacute ischemic stroke with intracranial artery stenosis.
Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent studies have indicated that intracranial stenting may positively affect the prognosis of patients with ischemic stroke. However, most patients included in these studies were in the hyperacute stage of ischemic stroke. Moreover, few studies with limited numbers of patients have examined the factors affecting the prognosis of patients with hyperacute stroke. Therefore, this study aimed to evaluate patient prognosis and factors associated with emergent intracranial stenting with the Enterprise 2 stent in patients with hyperacute ischemic stroke secondary to sudden intracranial artery occlusion.
methodsPatients with hyperacute ischemic stroke admitted to a single institution between January 2017 and December 2019 were retrospectively analyzed. Sixty-five patients with major intracranial artery occlusion associated with neurological deficits were selected. All patients underwent emergent intracranial stenting of the index artery after mechanical thrombectomy. We investigated the following composite outcomes: death, vessel reocclusion, and stroke recurrence.
resultsParticipants' mean age was 69.9 ± 12.3 years, and 57.6% were males. The middle cerebral artery was the most occluded (61.0%). The mean follow-up period was 8.4 ± 6.4 months; four patients developed arterial reocclusion. At the end of the follow-up period, the mean modified Rankin scale score was 4 and composite outcomes were observed in 14 patients.
conclusionsEmergent intracranial stenting using the Enterprise 2 stent resulted in a relatively favorable prognosis in patients with acute ischemic stroke. In addition, smoking status and the National Institutes of Health Stroke Scale score at admission were significant prognostic factors.
Indexed as
Identifiers
40272465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.